Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy

Table 2 Changes in hepatitis B virus-DNA, hepatitis B e antigen, hepatitis B surface antigen and alanine aminotransferase after anti-inflammatory and hepatoprotective treatment and antiviral therapy in patients with chronic hepatitis B and cirrhosis, n (%)

Variable	Chronic hepatitis B		Hepatitis B cirrhosis
	Observation group (n = 362)	Control group (n = 203)	Observation group (n = 96)		Control group (n = 129)
HBV-DNA undetectable	61 (16.85)	179 (87.19)		19 (19.79)	116 (89.92)
HBV-DNA drops no less than 2 log	216 (59.66)	194 (95.56)		57 (59.37)	124 (96.12)
HBeAg negative conversion	65 (32.82)	64 (52.03)		12 (40)	19 (59.37)
HBsAg negative conversion	3 (0.82)	2 (0.55)		1 (1.04)	2 (1.55)
ALT returns to normal	275 (75.96)	191 (94.08)		68 (70.83)	110 (85.27)

Undetectable hepatitis B virus-DNA was defined as hepatitis B virus-DNA < 500 copies/mL; a return of alanine aminotransferase to normal was defined as alanine aminotransferase < 40 mmol/L after treatment. HBV: Hepatitis B virus; ALT: Alanine aminotransferase; HBeAg: Hepatitis B e antigen; HBsAg: Hepatitis B surface antigen.